Loading
A phase 1/2 trial of Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by PDC*line Pharma SAS, active and no longer recruiting.
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC is a phase 1/2 interventional study registered as NCT03970746 by PDC*line Pharma SAS, with 73 participants enrolled, started 2019-09-10 and due to reach its primary completion in 2024-07-18. Interventions recorded: PDC*lung01, Keytruda Injectable Product, Alimta Injectable Product. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.